Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Expecting i quick drop to 0.006 which would signal the end of the P&D.. after that a continued downward fall as the toxic dumpers hit the 5 billion AS.. RS inevitable now. Should be announced within a few days / weeks
The Bitmain and Snap action certainly seems to be progressing.
Facebook action appears dead
I doubt they are mining with the current prices. Could come back when crypto goes up... who knows..
The Bitmain and Snap action certainly seems to be progressing.
Facebook action appears dead
I doubt they are mining with the current prices. Could come back when crypto goes up... who knows..
New OS 924,821,333
Thats yet another 50 million in just a day
Interesting, they now appear to be updating every day.
This is a dead stock..
From the last RS in February, the OS was at around 400k
It now sits at 3.1 billion as of beginning of September ( new number due any day )
The Note holders. Have diluted 3.1 billion shares. To claim there is no dilution is simply false.
Has anyone actually read the 8K, this is a minor development agreement between a company with zero revenue (OZSC) and a small Indian company (PPP)
There is no sales / revenue or anything just an agreement to develop future solutions
That’s it.... period
Under the terms of the Development Agreement, PPP shall provide certain specifications and design concepts to PCTI and PCTI shall design, engineer and develop one or more prototype(s) to be licensed to PPP for the manufacture and sale of certain products, which shall be based in whole or in part by the prototype(s).
This is a Conway stock, the pump is done,, the only way this is going to hit a higher PPS is via an RS.
The Indian company is tiny ( $2 mill total funded ). Basic DD shows the lie
I said 0,008 ( where it was before P&D ) not so crazy now.
Woot nearly 40% down on the big news day....
Oh wait.. it was the PR into the dump part of P&D.
All those whizzing to the moon should take note. The action here is not unprecedented, nor is it uncommon. You have picked a SCAM stock.. DD can prevent this ( read the fins and look for toxic notes )
If you can’t read a FIN and see this, try harder.
Will we break 0.0014 today.. I think so, but close a bit higher
Not an end.. just cycles.. and outer wheels.
We are approaching the 3rd cycle 0.001 / NOBID / Reverse Split
The outer wheel I think may play here., OMVS ( the 1st ) AITX ( 2nd ) .. needs the 3rd now
AITX is a 100% toxic stock, time to let go, bring in a new scam company so investors can continue to donate to Brian Conway
But but but. 3 years ago this was a $2 stock. Surely if we ignore the dilution and fundamentals and simply concentrate on a meaningless value we can make it happen...
Turn the machines back on...
According to Brian Conway , and Waypoint John ...
There is no Dilution... all the volume you have seen over the last few days is 100% retail.
First off, they would not know that unless Brian was illegally working directly with the note holders ( Which he is, but really should not be drawing attention to that ).
Second.. No dilution LMFO that’s all this and every other stock that Brain touched is. This company is designed at its core to sell toxic shares. There is nothing else worth anything.
The India company is tiny $2 million in capital... that’s it
Perspective please..
Share price back to all time low following the mini pump... should break to new lows now.
0.001 just around the corner
Did some basic DD on the Indian company (PPP), following the so called $124 million
Authorized Capital 1400.0 lakhs
Paid-up Capital 1170.5 lakhs
1 lakhs is 100,000 Rupees ( had to google that, could be wrong )
This sizes PPPs complete capital at just under $2 million. From what I can tell, it’s a well run small company.
This should point you to the REAL value of this deal to OZSC
A few thousands over 5 years. Assuming it goes ahead ( which it won’t )
No, like the price today tho.. anything out ?
Not really following closely anymore. I sold a few months back
I wish them well...
If i were to make a guess on the action today, I would say buying on the rumour, and the Note holders going into overdrive. By the end of the week it will be looking very ugly...
The huge blocks of Red volume on the chart yesterday would suggest the OS went up massively yesterday. At a guess 400-500 million... Regardless, the new OS number should be due soon, that will show how close OZSC is to the next inevitable RS
The AS is just short of 5 Billion
The OS last stated a month ago was 3.1 billion, but now should be over 4 Billion ( possibly near 5 )
It should be updated in a few days, they will also need an RS to knock it back to 400k like last time 1:1000 RS
OS number in context.
08/24/2018 Reverse 1:100
03/27/2020 Reverse 1:10000
3rd RS expected early 2021
Mid April. 400k. ( following 10000:1 RS was 4 billion)
Mid May. 2.3 Million
Mid June 17.2 Million
Mid July 152 million (Restated 196 Million)
Mid August 446 million
Mid September 774 Million (Restated 843 Million)
Mid October due in a month
Since April for every share in existence, they have diluted over 2000
OS prediction for Mid October . 1.2 Billion
Share Price expectation 0.001 and NO BID in October
Update to OS just 1 week after the last
843,309,432
70 million shares in just a few days.
Update to OS just 1 week after the last
843,309,432
Predict close around 0.008 or lower.. impressive volume generated by the toxic note holders... selling hundreds of millions today.
Well looking like the pump bit is done... it will fall quickly.. back to where it was within a few days
Also at 3.1 billion OS ... hitting the AS will be highly likely... OS due for update in a few days
Expect RS announcement soon after....
Not written by me, but keep in mind when dealing with AITX. Expecting a PR today where the context below should be a wake up call.
Toxic Funders are a common manipulative force in penny stocks trading. Hundreds of penny stocks are currently using toxic financing to fund operations and pay for insider expenses. These toxic instruments lead to massive amounts of dilution which is often accompanied by paid promotions (some with disclosed compensation and some without), social media pumps, and misleading/exagerrated/fraudulent press releases and public disclosures by the public Issuers.
The financiers target public Issuers that are rarely able to afford the funding and charge extremely high interest rates, processing fees, and penalties, but that’s the least of their clients’ problems. Upon conversion, the lenders enjoy a discount to market price that may be as high as 60 percent, and much higher in the event of default by the issuer. As the funder converts portions of the note and sells the resulting stock into the market in a series of tranches, the stock’s price plummets. That is why these kinds of instruments are called “death spiral convertibles.” Eventually, the dilution caused by the conversions may force the issuer to reverse split the company’s stock or even drive the company into bankruptcy.
Toxic funders have wreaked havoc with OTC companies for decades, but they’ve proved difficult for the SEC to rein in. In the past three years or so, however, the SEC has begun to pursue a new theory of these kinds of cases, invoking the funders’ failure to register as dealers. The SEC defines a dealer as “any person engaged in the business of buying and selling securities for his own account, through a broker or otherwise.” Individuals who buy and sell securities for themselves are usually considered to be “traders,” and are excepted from the dealer definition. What distinguishes a dealer from a trader is that the dealer “buys and sells as part of a regular business,” while a trader does not.
The bottom line is that toxic funders (i) don’t register as dealers, (ii) commit fraud by not making disclosures that they are not registered, (iii) wreak great harm on investors - (After all who buys the shares the funders dump?) and (iv) put thousands of businesses (including legitimate ones) out of business and/or force them into bankruptcy
Another not written by me, but know what you are dealing with on OZSC
Toxic Funders are a common manipulative force in penny stocks trading. Hundreds of penny stocks are currently using toxic financing to fund operations and pay for insider expenses. These toxic instruments lead to massive amounts of dilution which is often accompanied by paid promotions (some with disclosed compensation and some without), social media pumps, and misleading/exagerrated/fraudulent press releases and public disclosures by the public Issuers.
The financiers target public Issuers that are rarely able to afford the funding and charge extremely high interest rates, processing fees, and penalties, but that’s the least of their clients’ problems. Upon conversion, the lenders enjoy a discount to market price that may be as high as 60 percent, and much higher in the event of default by the issuer. As the funder converts portions of the note and sells the resulting stock into the market in a series of tranches, the stock’s price plummets. That is why these kinds of instruments are called “death spiral convertibles.” Eventually, the dilution caused by the conversions may force the issuer to reverse split the company’s stock or even drive the company into bankruptcy.
Toxic funders have wreaked havoc with OTC companies for decades, but they’ve proved difficult for the SEC to rein in. In the past three years or so, however, the SEC has begun to pursue a new theory of these kinds of cases, invoking the funders’ failure to register as dealers. The SEC defines a dealer as “any person engaged in the business of buying and selling securities for his own account, through a broker or otherwise.” Individuals who buy and sell securities for themselves are usually considered to be “traders,” and are excepted from the dealer definition. What distinguishes a dealer from a trader is that the dealer “buys and sells as part of a regular business,” while a trader does not.
The bottom line is that toxic funders (i) don’t register as dealers, (ii) commit fraud by not making disclosures that they are not registered, (iii) wreak great harm on investors - (After all who buys the shares the funders dump?) and (iv) put thousands of businesses (including legitimate ones) out of business and/or force them into bankruptcy
Excellent info, and thanks for setting this up.
Would it be worth including the worst OTC offenders. I know you follow Brian Conways stocks ( The Waypoint Refinery OZSC / AITX etc ) I’m sure there are many others ( too many to list ) but a set of the very worse would be useful.
Many Thanks...
FromTheUK
This is a dilution scam stock, OS goes up and up until they RS.
Latest pump promising deals always a couple of days away. Stock buybacks would be pointless, as the toxic notes would just sell to catch any uplift. Same with the pump.., give it a week and it will be lower than before.
Just think why would any legitimate company deal with a known scammer, or a company with zero revenue.
If it looks like a Turd and smells like a Turd....
I understand,
There is a huge difference between investment and short term OTC trading.
If you are playing the pump, and timed it well, I congratulate you. There is certainly money to be made trading even the most corrupt stocks on the OTC ( maybe even more ).
My focus is more longer term.
Another Update on Craig V Ira case
https://coingeek.com/ira-kleiman-attempts-to-delay-lynn-wright-probate-case/
Not written by me, but something you may find enlightening....
Brian Conway founded and owns The Waypoint Refinery.
It is an "investors relation" firm that uses non-SEC approved channels to pump stocks and lie to investors to facilitate dilution scams.
He uses the discord chat rooms to tell traders about press releases before they are released to the public and to mislead investors about things like the amount of dilution left, the value and state of operations, and his projections for the future (stock price, buybacks, revenues, etc.) all in an effort to make the traders feel special while he facilitates the dumping of billions of shares on their heads by the dilution funders he is really working for.
He literally lies and misleads hundreds of potential traders in those discord chat rooms to manipulate the share price of the stocks he pumps.
His use of the discord chat rooms to share insider information and mislead investors is a clear violation of Regulation FD and a clear violation of securities law.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156715063
Those discord chat rooms are clearly not available to all investors. The use of the chat rooms to share information not available to the general public has not been disclosed to the SEC. And by banning members that ask tough questions or speak negatively about the stocks being touted it prevents everybody from getting the information at the same time.
IMO it's currently one of the dirtiest stock pumping operations out there.
I look forward to the day the SEC files charges against Conway
A simple question, for a stock that is 40 million in debt, under heavy toxic notes, has a known serial scammer as CEO ( linked heavily to toxic notes ) and has ZERO revenue for the last six months ( from the FINS )
What would make anyone believe this deal is true. Who would ever deal with them except other crooks ?
Probably, how many of these P&D have you seen on this ticker so far.
They can run for 2-3 days, but this looks unlikely here, it’s a known Waypoint Scam stock, so bag holders will be limited. To the credit of the pump, it didn't sell off EOD, so I would expect at least a fake head up very early to try and pull the last few in.
As you say, should be interesting, but don’t completely ignore the possibility of it continuing up early doors.
Seen quite a few of these P&D now in Brian Conway / Waypoint Stocks. All designed to help sell Toxic Shares. They all end the same way. It will be ugly.
Ok loads of toxic notes, and zero revenue ... then surely there has to be a big pile of cash somewhere.
If there is, its not here.....
Accumulated Deficit (41,436,223)
So.. can someone please explain to me why this is a great investment ?
With millions in expenses and costs... the revenue must be really high yes ?
Nope
For the three and six months ended June 30, 2020, the Company did not recognize any revenues due to the termination of the agreements with SRI (see above). For the three and six months ended June 30, 2019, the Company generated total revenue of $1,521 and $ 49,123, respectively. The revenues are from the sale of spine surgery products. The decrease in revenues is a result of Spinus deciding to not to continue to supply its’ spine surgery products to the surgeon who previously performed surgeries with Spinus product. Revenues from Spinus are recognized as an agent and are recorded at net.
Thats right ZERO Revenue for the last 6 months.
So following March when they PRed how all the notes were cleared... They of course would NOT take out new ones would they.... that would be miss-leading..
Of course they did, Brian Coway Stocks always do.....
On March 9, 2020, (the “Issuance Date”) the Company issued a 12% convertible promissory note, in the principal amount of $80,000, to an investor. This note matures 6 months after the Issuance Date. This note is convertible into shares of the Company’s common stock beginning on the Issuance Date at $.25 for the first three months after the Issuance Date. After the first three months after the Issuance Date, the conversion price shall be equal to the lower of (i) $.25 or 50% of the lowest trading price for the thirty trading days prior to the conversion. The embedded conversion feature included in this note resulted in an initial debt discount of $57,000, interest expense of $64,067 and an initial derivative liability of $121,067. For the six months ended June 30, 2020, amortization of the debt discounts of $48,933 was charged to interest expense. As of June 30, 2020, the outstanding principal balance of this note was $80,000 with a carrying value of $48,933, net of unamortized discounts of $31,067.
On April 17, 2020, an investor (the “Purchaser”) pursuant to a Debt Purchase Agreement, purchased a past-due convertible note initially issued by the Company on December 5, 2018, and thereafter was acquired on June 5, 2019 (see above). The Purchaser acquired the note balance of $93,391. This note, as amended, is convertible into common stock at a conversion price equal to a 70% discount to the lowest closing prices of the common stock for thirty prior trading days including the day upon which a notice of conversion is received. The embedded conversion feature pursuant to this agreement resulted in interest expense of $1,476,436 (since the purchased note was past its’ maturity date and was in default) with the offset recorded to derivative liabilities. For the six months ended June 30, 2020, the Company recorded additional interest expense of $259,305 due to defaults of this note and the amount was added to the principal balance owed the Purchaser. As of June 30, 2020, the outstanding principal balance of assigned note was $352,695. This note was fully converted as of August 13, 2020.
On April 24, 2020, an investor (the “Purchaser”) pursuant to a Debt Purchase Agreement, purchased a past-due convertible note initially issued by the Company on October 19, 2018, and thereafter was acquired on June 7, 2019 (see above). The Purchaser acquired the note balance of $77,000. This note, as amended, is convertible into common stock at a conversion price equal to a 70% discount to the lowest closing prices of the common stock for thirty prior trading days including the day upon which a notice of conversion is received. The embedded conversion feature pursuant to this agreement resulted in interest expense of $881,058 (since the purchased note was past its’ maturity date and was in default) with the offset recorded to derivative liabilities. For the six months ended June 30, 2020, the Company recorded additional interest expense of $121,250 due to defaults of this note and the amount was added to the principal balance owed the Purchaser. For the six months ended June 30, 2020, the investor converted a total of $198,183 of the face value and $44,396 of accrued interest and fees into 179,688,215 shares of common stock at an average conversion price of $0.00131. As of June 30, 2020, the outstanding principal balance of assigned note was $67.
On April 27, 2020, the Company issued a 15% convertible redeemable note in the principal amount of $60,000. This note matures on April 27,2021 and is convertible into shares of common stock at a conversion price equal to 50% of the lowest traded price for the twenty-five prior trading days including the day upon which a conversion notice is received by the Company. This note was funded on April 27, 2020, when the Company received proceeds of $50,000, after OID of $10,000, which was recorded as a discount against the debt to be amortized into interest expense through maturity. The embedded conversion feature included in this note resulted in an initial debt discount of $50,000, interest expense of $36,274 and an initial derivative liability of $86,274. For the six months June 30, 2020, amortization of the debt discounts of $10,000 was charged to interest expense. As of June 30, 2020, the outstanding principal balance of this note was $60,000 with a carrying value of $10,000, net of unamortized discounts of $50,000.
On April 28, 2020, an investor (the “Purchaser”) pursuant to a Debt Purchase Agreement, purchased a convertible note issued by the Company on August 23, 2019 with a maturity date of May 23, 2020 (see above). The Purchaser acquired $13,483 of this note. This note, as amended, is convertible into common stock at a conversion price equal to a 70% discount to the lowest closing prices of the common stock for thirty prior trading days including the day upon which a notice of conversion is received. The embedded conversion feature pursuant to this agreement resulted in an initial debt discount of $13,483, interest expense of $42,261 and an initial derivative liability of $55,744. For the six months ended June 30, 2020, the Company recorded additional interest expense of $1,348 due to a default of this note and the amount was added to the principal balance owed the Purchaser. For the six months ended June 30, 2020, amortization of the debt discounts of $13,483 was charged to interest expense. As of June 30, 2020, the outstanding principal balance of assigned note was $14,831.
22
On April 28, 2020, the Company issued a 12% convertible promissory note, (the “Note”) in the principal amount of $53,000, pursuant to a Securities Purchase Agreement we entered into with an investor. This note matures 12 months after the date of issuance. This note is convertible into shares of the Company’s common stock beginning on the date which is 180 days from the issuance date of this note, at a conversion price equal to 58% multiplied by the lowest closing bid price during the 20- trading day period ending on the last completed trading date in the OTC Markets prior to the date of conversion. The Company received proceeds of $50,000 (including direct payments from the lender to certain Company vendors) on May 4, 2020, and the Company reimbursed the investor for expenses for legal fees and due diligence of $3,000. This note proceeds will be used by the Company for general working capital purposes. The embedded conversion feature included in this note resulted in an initial debt discount of $50,000, interest expense of $1,539 and an initial derivative liability of $51,539. For the six months June 30, 2020, amortization of the debt discounts of $8,833 was charged to interest expense. As of June 30, 2020, the outstanding principal balance of this note was $53,000 with a carrying value of $8,833, net of unamortized discounts of $44,167.
On May 4, 2020, the Company issued a 12% convertible promissory note, (the “Note”) in the principal amount of $110,000, pursuant to a Securities Purchase Agreement we entered into with an investor. This note matures 12 months after the date of issuance. This note is convertible into shares of the Company’s common stock beginning on the date which is 180 days from the issuance date of this note, at a conversion price equal to the lower of $0.50 or 58% multiplied by the average of the two lowest closing trading price or bid price during the 20- trading day period ending on the last completed trading date in the OTC Markets prior to the date of conversion. The Company received proceeds of $96,250 on May 6, 2020, and the Company reimbursed the investor for expenses for legal fees and due diligence of $13,750. This note proceeds will be used by the Company for general working capital purposes. In conjunction with this note, the Company issued a warrant to purchase 3,666,666 shares of common stock at an exercise price of $0.015, subject to adjustments and expiring on the five-year anniversary of the Issuance Date. The embedded conversion feature included in this note resulted in an initial debt discount of $100,000, interest expense of $5,526 and an initial derivative liability of $105,526. For the six months ended June 30, 2020, amortization of the debt discounts of $18,792 was charged to interest expense. As of June 30, 2020, the outstanding principal balance of this note was $110,000 with a carrying value of $16,042, net of unamortized discounts of $93,958.
On May 5, 2020, (the “Issuance Date”) the Company issued a 12% convertible promissory note, (the “Note”) in the principal amount of $162,000, to an investor. This note matures 6 months after the Issuance Date. This note is convertible into shares of the Company’s common stock beginning on the Issuance Date at $03 for the first three months after the Issuance Date. After the first three months after the Issuance Date, the conversion price shall be equal to the lower of (i) $.03 or 50% of the lowest trading price for the thirty-five trading days prior to the conversion. The Company received proceeds of $100,000 on May 13, 2020, and this note included an original issue discount of $62,000. This note proceeds will be used by the Company for general working capital purposes. The embedded conversion feature included in this note resulted in an initial debt discount of $100,000, interest expense of $151,512 and an initial derivative liability of $251,512. For the six months ended June 30, 2020, amortization of the debt discounts of $54,000 was charged to interest expense. As of June 30, 2020, the outstanding principal balance of this note was $162,000 with a carrying value of $54,000, net of unamortized discounts of $108,000. In conjunction with this note, the Company issued a warrant to purchase 4,325,000 shares of common stock at an exercise price of $0.02, subject to adjustments and expiring on the five-year anniversary of the Issuance Date.
On May 7, 2020, the Company issued a 15% convertible redeemable note in the principal amount of $30,000. This note matures on May 7,2021 and is convertible into shares of common stock at a conversion price equal to 50% of the lowest traded price for the twenty-five prior trading days including the day upon which a conversion notice is received by the Company. The Company received proceeds of $25,000 on May 7, 2020, and this note included an original issue discount of $5,000, which was recorded as a discount against the debt to be amortized into interest expense through maturity This note proceeds will be used by the Company for general working capital purposes. The embedded conversion feature included in this note resulted in an initial debt discount of $25,000, interest expense of $17,828 and an initial derivative liability of $42,828. For the six months June 30, 2020, amortization of the debt discounts of $4,375 was charged to interest expense. As of June 30, 2020, the outstanding principal balance of this note was $30,000 with a carrying value of $4,375, net of unamortized discounts of $25,625.
23
On May 7, 2020, an investor (the “Purchaser”) pursuant to a Debt Purchase Agreement, purchased a convertible note issued by the Company on October 24, 2019, with a maturity date of October 24, 2020 (see above). The Purchaser acquired $200,000 of this note. This note, as amended, is convertible into common stock at a conversion price equal to a 70% discount to the lowest closing prices of the common stock for thirty prior trading days including the day upon which a notice of conversion is received. The embedded conversion feature pursuant to this agreement resulted in an initial debt discount of $200,000, interest expense of $111,128 and an initial derivative liability of $311,128. For the six months ended June 30, 2020, amortization of the debt discounts of $200,000 was charged to interest expense. For the six months ended June 30, 2020, the investor converted a total of $200,000 of the face value and $16,922 of accrued interest and fees into 92,332,507 shares of common stock at an average conversion price of $0.00218. As of June 30, 2020, the outstanding principal balance of assigned note was $-0-.
On May 15, 2020, an investor (the “Purchaser”) pursuant to a Debt Purchase Agreement, purchased a convertible note initially issued by the Company on January 8, 2020, with a maturity date of January 8, 2021 (see above). The Purchaser paid $52,000 for the note. This note, as amended, is convertible into common stock at a conversion price equal to a 70% discount to the lowest closing prices of the common stock for thirty prior trading days including the day upon which a notice of conversion is received. For the six months ended June 30, 2020, the Company recorded additional interest expense of $63,500 due to defaults of this note and the amount was added to the principal balance owed the Purchaser. The embedded conversion feature pursuant to this agreement resulted in an initial debt discount of $100,000, interest expense of $526,507 and an initial derivative liability of $626,507. For the six months ended June 30, 2020, amortization of the debt discounts of $25,000 was charged to interest expense. For the six months ended June 30, 2020, the investor converted a total of $66,454 of the face value and $5,246 of accrued interest and fees into 53,110,926 shares of common stock at an average conversion price of $0.00129. As of June 30, 2020, the outstanding principal balance of assigned note was $83,546, with a carrying value of $8,546, net of unamortized discounts of $75,000. This note was fully converted as of August 13, 2020.
On May 15, 2020, an investor (the “Purchaser”) pursuant to a Debt Purchase Agreement, purchased a convertible note initially issued by the Company on November 27, 2019, with a maturity date of November 27, 2020 (see above). The Purchaser paid $75,000 for the note. This note, as amended, is convertible into common stock at a conversion price equal to a 70% discount to the lowest closing prices of the common stock for thirty prior trading days including the day upon which a notice of conversion is received. For the six months ended June 30, 2020, the Company recorded additional interest expense of $75,000 due to defaults of this note and the amount was added to the principal balance owed the Purchaser. The embedded conversion feature pursuant to this agreement resulted in an initial debt discount of $77,000, interest expense of $388,385 and an initial derivative liability of $465,385. As of June 30, 2020, the outstanding principal balance of assigned note was $115,500, with a carrying value of $52,398, net of unamortized discounts of $62,563. This note was fully converted as of August 13, 2020.
On May 28, 2020, the Company issued a 15% convertible redeemable note in the principal amount of $30,000. This note matures on May 28, 2021 and is convertible into shares of common stock at a conversion price equal to 50% of the lowest traded price for the twenty-five prior trading days including the day upon which a conversion notice is received by the Company. The Company received proceeds of $25,000 on May 28, 2020, and this note included an original issue discount of $5,000. This note proceeds will be used by the Company for general working capital purposes. The embedded conversion feature included in this note resulted in an initial debt discount of $25,000, interest expense of $19,346 and an initial derivative liability of $44,346. For the six months June 30, 2020, amortization of the debt discounts of $2,500 was charged to interest expense. As of June 30, 2020, the outstanding principal balance of this note was $30,000 with a carrying value of $2,500, net of unamortized discounts of $27,500.
On May 28, 2020, an investor (the “Purchaser”) pursuant to a Debt Purchase Agreement, purchased a convertible note issued by the Company on May 29, 2019 (see above). The Purchaser acquired $67,365 of this note. This note, as amended, is convertible into common stock at a conversion price equal to a 70% discount to the lowest closing prices of the common stock for thirty prior trading days including the day upon which a notice of conversion is received. The embedded conversion feature pursuant to this agreement resulted in an initial debt discount of $67,365, interest expense of $443,420 and an initial derivative liability of $510,785. For the six months ended June 30, 2020, the Company recorded additional interest expense of $83,395 due to defaults of this note and the amount was added to the principal balance owed the Purchaser. For the six months ended June 30, 2020, amortization of the debt discounts of $67,365 was charged to interest expense. For the six months ended June 30, 2020, the investor converted a total of $47,090 of the face value and $3,000 of accrued interest and fees into 39,959,295 shares of common stock at an average conversion price of $0.00118. As of June 30, 2020, the outstanding principal balance of assigned note was $103,671. This note was fully converted as of August 13, 2020.
24
On June 1, 2020, (the “Issuance Date”) the Company issued a 12% convertible promissory note, (the “Note”) in the principal amount of $127,500, to an investor. This note matures 6 months after the Issuance Date. This note is convertible into shares of the Company’s common stock beginning on the Issuance Date at $0.025 for the first three months after the Issuance Date. After the first three months after the Issuance Date, the conversion price shall be equal to the lower of (i) $.025 or 50% of the lowest trading price for the thirty-five trading days prior to the conversion. The Company received proceeds of $100,000 on June 1, 2020, and this note included an original issue discount of $27,500. This note proceeds will be used by the Company for general working capital purposes. The embedded conversion feature included in this note resulted in an initial debt discount of $100,000, interest expense of $103,250 and an initial derivative liability of $203,250. For the six months ended June 30, 2020, amortization of the debt discounts of $21,250 was charged to interest expense. As of June 30, 2020, the outstanding principal balance of this note was $127,500 with a carrying value of $21,250, net of unamortized discounts of $106,250. In conjunction with this note, the Company issued a warrant to purchase 6,375,000 shares of common stock at an exercise price of $0.02, subject to adjustments and expiring on the five-year anniversary of the Issuance Date.
On June 11, 2020, the Company issued a 12% convertible promissory note, (the “Note”) in the principal amount of $53,000, pursuant to a Securities Purchase Agreement we entered into with an investor. This note matures 12 months after the date of issuance. This note is convertible into shares of the Company’s common stock beginning on the date which is 180 days from the issuance date of this note, at a conversion price equal to 58% multiplied by the lowest closing bid price during the twenty trading day period ending on the last completed trading date in the OTC Markets prior to the date of conversion. The Company received proceeds of $50,000 on June 12, 2020, and the Company reimbursed the investor for expenses for legal fees and due diligence of $3,000. This note proceeds will be used by the Company for general working capital purposes. The embedded conversion feature included in this note resulted in an initial debt discount of $50,000, interest expense of $2,218 and an initial derivative liability of $52,218. For the six months June 30, 2020, amortization of the debt discounts of $2,849 was charged to interest expense. As of June 30, 2020, the outstanding principal balance of this note was $53,000 with a carrying value of $2,849, net of unamortized discounts of $50,151.
On June 23, 2020, an investor (the “Purchaser”) pursuant to a Debt Purchase Agreement, purchased a past-due convertible note initially issued by the Company on October 6, 2017 (see above). The Purchaser paid $60,000 for the note. This note, as amended, is convertible into common stock at a conversion price equal to a 70% discount to the lowest closing prices of the common stock for thirty prior trading days including the day upon which a notice of conversion is received. For the six months ended June 30, 2020, the Company recorded additional interest expense of $52,500 due to defaults of this note and the amount was added to the principal balance owed the Purchaser. The embedded conversion feature pursuant to this agreement resulted in interest expense of $658.093 (since the purchased note was past its’ maturity date and was in default) with the offset recorded to derivative liabilities. For the six months ended June 30, 2020, the investor converted a total of $91,579 of the face value and $42,071 of accrued interest and fees into 99,000,000 shares of common stock at an average conversion price of $0.00133. As of June 30, 2020, the outstanding principal balance of assigned note was $20,921. This note was fully converted as of August 13, 2020.
On June 30, 2020, (the “Issuance Date”) the Company issued a 15% convertible promissory note, (the “Note”) in the principal amount of $129,500, to an investor. This note matures 6 months after the Issuance Date. This note is convertible into shares of the Company’s common stock beginning on the Issuance Date at $0.025 for the first three months after the Issuance Date. After the first three months after the Issuance Date, the conversion price shall be equal to the lower of (i) $.025 or 50% of the lowest trading price for the thirty-five trading days prior to the conversion. The Company received proceeds of $102,000 on July 1, 2020, and this note included an original issue discount of $27,500 and lender costs of $2,000. This note proceeds will be used by the Company for general working capital purposes. The embedded conversion feature included in this note resulted in an initial debt discount of $100,000, interest expense of $107,122 and an initial derivative liability of $207,122. As of June 30, 2020, the outstanding principal balance of this note was $129,500 with a carrying value of $-0-, net of unamortized discounts of $129,500. In conjunction with this note, the Company issued a warrant to purchase 6,375,000 shares of common stock at an exercise price of $0.02, subject to adjustments and expiring on the five-year anniversary of the Issuance Date.
In Feb a 1:1000 RS bringing the OS right down
In March the following PR showing how Dilution would be ended ( almost )
https://www.globenewswire.com/news-release/2020/05/13/2032681/0/en/OZSC-Announces-Successful-Reduction-of-Note-Holders-by-Almost-80.html
Since then, what has the stock with a serial Scammer as a CEO done.. pumped by the Waypoint Refinery that he also founded.. ?
OS quickly approaching the AS yet again... nothing changed.. the scam continues. SP plummets
Dont let a planned P&D fool you..